



AnaptysBio

*Leader in SHM for
Antibody Therapeutics*

FOR IMMEDIATE RELEASE

July 12, 2010

**DARPA AWARDS ANAPTYSBIO UP TO \$1.5 MILLION
TO GENERATE HIGH AFFINITY THERMALLY STABLE ANTIBODIES**

***Proprietary somatic hypermutation (SHM) platform to generate
novel antibodies for detecting toxic substances, bioterrorist threats***

SAN DIEGO, CA – AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced it has been awarded a contract by the Defense Advanced Research Projects Agency (DARPA), to use its proprietary somatic hypermutation (SHM) technology platform to generate novel high affinity thermally stable antibodies that could be used by the military in antibody-based biosensors, including those that can detect bioterrorist threats.

AnaptysBio has the potential to receive up to \$1.5 million for work anticipated to be conducted over a two year period under the contract with DARPA, a U.S. Department of Defense agency tasked to prevent and create technological surprise in support of national security.

Biosensors allow for rapid detection of target molecules, providing high levels of sensitivity and specificity. For example, in environmental monitoring, biosensors can sense toxic substances, such as airborne bacteria, pesticides and water contaminants. For military applications, biosensors can be used to detect potential bioterrorist threats. Antibodies, due to their high affinity and exquisite specificity, have become a preferred component for use in a wide variety of biosensors. Although highly versatile, use of conventional antibodies in biosensors has often been limited by stability issues such as sensitivity to heat.

“The military often operates under harsh conditions that can shorten the useful life of important safety-related equipment such as antibody-based biosensor instruments capable of detecting trace amounts of toxic substances,” said Tom Smart, chairman and chief executive officer for AnaptysBio. “Using our SHM-Platform™, we have the potential to revolutionize the way antibodies are generated or improved, in this case enabling the generation of thermally stable antibodies for use in biosensors with full retention of functionality. The results also may have applications within the pharmaceutical industry for more flexible and less costly formulation and storage requirements for therapeutic antibodies.”

About AnaptysBio

Founded in 2005, AnaptysBio, Inc is a privately-held therapeutic antibody product company and the leader in the use of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body’s natural process for generating potent antibodies to fight disease. The Company’s SHM-Platform™ utilizes the key components of SHM and other state-of-the-art techniques such as

mammalian cell expression/surface display and flow cytometry to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection – a process that has been referred to as “naturalizing” antibodies. This versatile platform can be used both to discover and optimize antibodies directed at specific disease targets and also affinity mature existing antibodies to improve their binding properties. The company has established broad intellectual property around the use of SHM for therapeutic antibody applications, and is currently building a pipeline of novel therapeutic antibody product candidates. For more information, visit www.anaptysbio.com.

Contacts:

Gable PR – 619-284-1714

Tom Gable

tom@gablepr.com

Cell: 619-251-3881